Comparative cellular DNA content measurements have been done on two sites differing from each other in their anatomical location, in 16 cases of gastric cancer by means of microphotometry. In addition, comparisons on the DNA stemline of the original gastric lesions and their metastatic lesions (8 cases of liver metastases and 9 cases of lymph node metastases) also were done. The main stemlines in four cases (25%) out of 16 gastric cancers exhibited different main DNA stemlines from the other sites in the same lesion, although in the other 12 cases examined, two sites showed the same DNA stemlines to each other. In almost all cases, the DNA stemlines of the metastatic foci were consistent with those of the original lesions. The lymph node metastases simulated the original lesions in its DNA stemlines (89%) more than did the cases of livermetastases (63%). In an exceptional case, the original lesion exhibited two definite stemlines (2C & 3.5C), but only one (2C) was recognizable in the metastatic focus of the liver. This difference indicates the probable role of "clonal selection" in a blood-borne metastasis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dna stemlines
16
dna content
8
gastric cancer
8
lymph node
8
node metastases
8
stemlines cases
8
original lesions
8
dna
7
cases
7
stemlines
6

Similar Publications

This study aimed to evaluate the impact of the myelodysplasia-related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with -mutated ( ) AML. Targeted DNA sequencing of 263 genes was performed in 568 AML patients (median age: 59 years) entered into the prospective AMLSG 09-09 treatment trial. Most commonly co-mutated genes were (49.

View Article and Find Full Text PDF

Background: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer.

View Article and Find Full Text PDF

Background: Early-phase clinical trials offer a unique opportunity for patients with cancer. These trials often mandate biopsies to collect tumor tissue for research purposes, requiring patients to undergo invasive procedures. Some trials mandate molecular prescreening, but the success of these analyses relies on the quality and quantity of the tested materials.

View Article and Find Full Text PDF

Background: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial.

View Article and Find Full Text PDF

Patients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response. Among 400 ND-AML patients treated with Ven-HMA at the Mayo Clinic, 247 (62%) achieved complete remission with (CR) or without (CRi) count recovery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!